2013年以来、クラリベイトの専門家は、注目すべき医薬品を毎年発表しています。基本的な考え方は変わらず、手法の変更はほとんどありませんが、医薬品のタイムラインと成功率の予測分析など、新しいツールが分析に役立つようになっています。
| Drug name | Company | Therapy area | Year |
| Capivasertib | AstraZeneca plc | Breast cancer | 2023 |
| Daprodustat | GlaxoSmithKline plc | Chronic kidney disease (CKD)–related anemia | 2023 |
| Deucravacitinib | Bristol-Myers Squibb Co. | Plaque psoriasis | 2023 |
| Foscarbidopa/foslevodopa | AbbVie Inc. | Parkinson’s disease | 2023 |
| Lenacapavir | Gilead Sciences Inc. | HIV | 2023 |
| Pegcetacoplan | Apellis Pharmaceuticals Inc. | Geographic atrophy (GA), Paroxysmal nocturnal hemoglobinuria (PNH) | 2023 |
| Ritlecitinib | Pfizer Inc. | Alopecia areata | 2023 |
| Sparsentan | Travere Therapeutics Inc | Focal segmental glomerulosclerosis (FSGS), IgA nephropathy | 2023 |
| Teplizumab | Provention Bio Inc | Type 1 diabetes mellitus (T1DM) | 2023 |
| Valoctocogene roxaparvovec | Biomarin Pharmaceutical Inc. | Hemophilia A | 2023 |
| Teclistamab | Janssen Pharmaceutical | Multiple myeloma | 2023 |
| Adagrasib | Mirati Therapeutics, Zai Lab Limited | KRASG12C-positive NSCLC and CRC | 2022 |
| Donanemab | Mirati Therapeutics, Zai Lab Limited | Alzheimer’s disease | 2022, 2023 |
| Faricimab | Roche and Chugai Pharmaceutical | Diabetic macular edema and wet age-related macular degeneration | 2022 |
| Lecanemab | Mirati Therapeutics, Zai Lab Limited | Alzheimer’s disease | 2022, 2023 |
| Tezepelumab | Mirati Therapeutics, Zai Lab Limited | Severe asthma | 2022 |
| Tirzepatide | Mirati Therapeutics, Zai Lab Limited | Type 2 diabetes mellitus | 2022 |
| Vutrisiran | Mirati Therapeutics, Zai Lab Limited | Transthyretin-mediated amyloidosis-related polyneuropathy | 2022 |
| Aducanumab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease, Neurology/psychiatric | 2021 |
| Vericiguat | Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |
| Relugolix | ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | Oncology - prostate cancer, Reproductive health - endometriosis & uterine fibroids | 2021 |
| Bimekizumab | UCB | Excessive immune response/autoimmunity, Psoriasis | 2021, 2023 |
| Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
| Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | Cardiovascular disease | 2020 |
| Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | Oncology | 2020 |
| Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
医薬品および生物製剤の世界市場における重要な発展には、AI と遺伝子治療の台頭、インフレ抑制法の影響、バイオシミラーの成熟、治療薬のイノベーションにおけるリアルワールドデータの可能性などが含まれます。